Rp-Hplc Method Development And Validation For The Combination Of Imiquimod And Salicylic Acid
Int J Pharm Pharm Sci
;
2020 Sep; 12(9): 41-48
Artigo
| IMSEAR
| ID: sea-206027
ABSTRACT
Objective:
The present study was undertaken to develop and validate an RP-HPLC method for the combination of imiquimod and salicylic acidMethods:
The method was carried out on Nucleodur C18 (250 mm × 4.6 mm I.D., 5 ????m) using low-pressure gradient elution mode. The mobile phase was used as 30M potassium dihydrogen phosphate and acetonitrile (4555) pH 6.5 adjusted using ortho-phosphoric acid. The concentration of solvents was 1-20 µg/ml and the volume of injection was 20 mcl with the flow rate of 1.0 ml/min. The absorption maxima of salicylic acid and imiquimod were found 234 nm and 226 nm, respectively.Results:
The method was validated and showed the linearity greater than 0.99% and with precision (RSD%<1). The limit of detection (LOD) and limit of quantification (LOQ) of salicylic acid was found to be 0.09756 µg/ml and 0.2956 µg/ml, respectively, and imiquimod was found to be 0.044031 µg/ml and 0.13334 µg/ml, respectively.Conclusion:
The method developed in the present study was found to be sensitive, specific, and can be applied for the simultaneous estimation of imiquimod and salicylic acid.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Revista:
Int J Pharm Pharm Sci
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS